DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Luca Issi - 3 Issi - 1 Issi's - 1 Issa - 1 GSD1a - 1 Andrew Kelly - 1 patisiran - 1 ATTR amyloidosis - 1
Top related locs:
U.S Bengaluru White Oak , Maryland Massachusetts United States California Tyler Van Buren
Top related orgs:
U.S . Food - 2 Drug Administration - 2 Alnylam Pharmaceuticals - 2 Thomson - 2 Ultragenyx Pharmaceutical - 1 RBC Capital Markets - 1 Food and Drug Administration - 1 FDA - 1

Search resuls for: "Luca Issi"


4 mentions found


☆ Buy this little-known pharma stock with more than 80% upside ahead, RBC says
  + stars: | 2024-04-22 | by ( Pia Singh | ) www.cnbc.com   time to read: +3 min
Ultragenyx Pharmaceutical has several growth opportunities ahead that could lead its share price to boom over the next year, according to RBC Capital Markets. Analyst Luca Issi initiated research coverage of the pharmaceutical company, which develops treatments for rare and ultra-rare diseases, with an outperform rating and $77 price target. Ultragenyx is forecasting between $500 million and $530 million in revenue for 2024, driven by rare bone disease drug Crysvita, long-chain fatty acid oxidation disorder drug Dojolvi, as well as therapies Mepsevii and Evkeeza. The analyst is also looking ahead to Ultragenyx's treatments for Angelman syndrome, Glycogen storage disease type 1, or GSD1a, plus Wilson's disease as potential opportunities to drive up the stock. Wilson's disease is a rare genetic disorder that prevents the body from eliminating copper, which then leads it to accumulate in the liver, brain and other organs.
Persons: Luca Issi, Issi, Issi's, Issa, GSD1a Organizations: Ultragenyx Pharmaceutical, RBC Capital Markets, U.S . Food, Drug Administration
☆ Alnylam gives up on expanded use of heart-disease drug in US after FDA declines approval
  + stars: | 2023-10-09 | by ( Mariam E Sunny | ) www.reuters.com   time to read: +2 min
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. The FDA, in 2019, approved Pfizer's (PFE.N) oral drug tafamidis, sold under the brand names Vyndaqel and Vyndamax, to treat transthyretin amyloid cardiomyopathy in the United States. Alnylam said it will focus on another drug candidate, vutrisiran, an under-the-skin injection in late-stage trials to treat ATTR amyloidosis-related cardiomyopathy. Branded as Amvuttra, vutrisiran is also approved in the U.S. to treat nerve damage in adult patients with hereditary ATTR amyloidosis. William Blair analyst Myles Minter estimates peak U.S. sales of $2.2 billion for vutrisiran as an ATTR cardiomyopathy treatment.
Persons: Andrew Kelly, patisiran, ATTR amyloidosis, Alnylam, Luca Issi, ATTR, William Blair, Myles Minter, Mariam Sunny, Pooja Desai Organizations: Food and Drug Administration, FDA, REUTERS, Alnylam Pharmaceuticals, RBC, Thomson Locations: White Oak , Maryland, U.S, Massachusetts, United States, Bengaluru
☆ BridgeBio's heart disease drug meets late-stage study goal, shares soar
  + stars: | 2023-07-17 | by ( Khushi Mandowara | ) www.reuters.com   time to read: +2 min
July 17 (Reuters) - BridgeBio Pharma Inc's (BBIO.O) experimental drug for a rare heart disease showed significant improvement in patients in a late-stage study, sending its shares surging 65% on Monday. BridgeBio's drug improved survival by 81% in the study patients compared to 74% on the placebo, and also reduced frequency of heart disease-related hospitalization by 50%. The California-based company also provided additional data comparing it with Pfizer's drug. Acoramidis showed 92% improvement on heart failure test, compared to patients on placebo and Pfizer's drug at 30 months. The additional data suggests that BridgeBio's drug was better than tafamidis in controlling the disease, said TD Cowen analyst Tyler Van Buren.
Persons: acoramidis, Acoramidis, Cowen, Tyler Van, Luca Issi, BridgeBio, BridgeBio's, Khushi, Nivedita Bhattacharjee Organizations: BridgeBio Pharma, Alnylam Pharmaceuticals, Ionis Pharmaceutical, RBC Capital, U.S . Food, Drug Administration, Thomson Locations: U.S, California, Tyler Van Buren, Bengaluru
☆ Here are some of RBC's top stock picks for the second quarter
  + stars: | 2023-04-06 | by ( Hakyung Kim | Https | Www.Linkedin.Com In Hakyungkim | ) www.cnbc.com   time to read: +3 min
RBC Capital Markets anticipates that the next quarter could be choppy for stocks, but the firm shared its list of high-conviction names to navigate the volatility. With these concerns in mind, RBC shared a list of high-conviction stocks that it says are well-positioned to offer upside this quarter. Below are 10 of the names: Alnylam Pharmaceuticals and biotech engineering stock Boston Scientific are new additions to RBC's list of high-conviction names. RBC analyst Shagun Singh said Boston Scientific is "positioned to drive consistent double-digit EPS growth," with upcoming device launches and trial data readouts to act as catalysts. On the energy front, RBC named oil company Diamondback Energy as one of its top picks for the quarter.
0 next >>
Total: 4